

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application: Robert M. Jones et al.

Confirmation No: 4098

Serial No.: 10/541,657

Group Art Unit: 1624

Filed: January 14, 2004(Intl. Filing Date)


Examiner: Not Yet Assigned

For: 1,2,3-TRISUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS  
MODULATORS OF METABOLISM AND THE PROPHYLAXIS AND TREATMENT  
OF DISORDERS RELATED THERETO SUCH AS DIABETES AND  
HYPERGLYCEMIA

Certificate of Mailing

I hereby certify that this correspondence,  
22 citation sheets listing 386 references, and 342  
references are being provided in seven (7) separate  
boxes, are being Deposited with the United States  
Postal Service as first class mail addressed to: Mail  
Stop PCT, Commissioner for Patents, Washington,  
DC 20231  
On this date

February 27, 2007

By:   
Susanne H. Goodson, Ph.D.  
Registration No.: 58,450

**MAIL STOP PCT**  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

**INFORMATION DISCLOSURE STATEMENT**

Pursuant to 37 C.F.R. §§ 1.56 and in accordance with 37 C.F.R. §§ 1.97 and 1.98, information relating to the above-identified application is hereby disclosed, the Examiner in charge of the above-identified application is requested to consider and make of record the references listed on the PTO Forms SB/08A and SB/08B, formerly known as PTO Form 1449, submitted herewith.

Inclusion of the information submitted herewith is not to be construed as an admission that the information is material as that term is defined in 37 C.F.R. § 1.56(b).

In accordance with 37 C.F.R. § 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.M./

**This Information Disclosure Statement is being filed:**

- within three months of the filing date of the patent application.
- within three months of the date of entry into the national stage as set forth in 37 C.F.R. § 1.491 of the international application.
- before the mailing date of a first Office Action on the merits.
- after the mailing date of a first Office Action on the merits, but before the mailing date of a Final Office Action under 37 C.F.R. § 1.116 or a Notice of Allowance under 37 C.F.R. § 1.311, and accordingly is accompanied by:
  - the Statement under 37 C.F.R. § 1.97(e) (see "Statement" below);  
**or**
  - the Fee of \$180.00 set forth in 37 C.F.R. § 1.17(p); or
  - No fee is owed by the applicant(s).
- In accordance with 37 C.F.R. § 1.129(a), this Information Disclosure Statement is being filed in connection with  the first or  second After Final Submission, and accordingly is accompanied by the Statement under 37 C.F.R. § 1.97(e) (see "Statement" below) and the fee of \$180.00 as set forth in 37 C.F.R. § 1.17(p), is attached.
- after the mailing date of a Final Office Action under 37 C.F.R. § 1.116 or a Notice of Allowance under 37 C.F.R. § 1.311, but before the payment of the Issue Fee, and accordingly is accompanied by the Statement under 37 C.F.R. § 1.97(e), (see "Statement," and "Fees" below).
- Copies of the references (excluding the U.S. Patent Documents) listed on the attached PTO Forms SB/08a and SB/08b, formerly known as PTO Form 1449, are enclosed.

**EXCEPT THAT:**

- In view of the voluminous nature of references **JF, LX, ME, PI, PJ, and, PK** and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.

- In accordance with 37 C.F.R. § 1.98(d), copies of the following references listed on the attached PTO Form SB/08A and PTO Form SB/08B, formerly known as PTO Form 1449 are not enclosed herewith because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application(s) for which a claim for priority under 35 U.S.C. § 120 have been made in the instant application.
- If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.

**Statement under 37 C.F.R. § 1.97(e)**

- The undersigned attorney hereby states that each item information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign patent application not more than three months prior to the filing of the Information Disclosure Statement.

**Fees**


- No Fee is owed by the applicant(s).
- The Information Disclosure Statement Fee of \$180.00 under 37 C.F.R. § 1.17(p) is enclosed herewith.

**Method of Payment of Fees**

- Attached is a check in the amount of \$\_\_\_\_\_ . This form is submitted in duplicate.
- Charge Deposit Account No. 50-1275 in the amount of \$180.00. This form is submitted in duplicate.
- Please charge any deficiency or credit any overpayment to Deposit Account 50-1275.

- No fee or Statement is required under 37 C.F.R. § 1.97(b) as no first Office Action on the merits has been received by Applicants.

Respectfully submitted,

  
Susanne Hoff Goodson  
Susanne Hoff Goodson, Ph.D.  
Registration No. 58,450

Dated: February 27, 2007

COZEN O'CONNOR, P.C.  
1900 Market Street, 5<sup>th</sup> Floor  
Philadelphia, PA 19103-3508  
(215) 665-2000 - Telephone  
(215) 665-2013 - Facsimile

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**Complete if Known****INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Application Number	10/541,657
Filing Date	January 14, 2004
First Named Inventor	Robert M. Jones
Art Unit	1624
Examiner Name	To Be Determined

Sheet

1

of

22

Attorney Docket Number

AREN34.US5.PCT

**U.S. PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Document Number	Publication/Issue Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
	AA	US-3,503,963	03-31-1970	Schweizer, et al.	
	AB	US-3,592,932	07-13-1997	Duerr et al.	
	AC	US-3,608,087	09-21-1971	Patchett et al.	
	AD	US-3,686,238	08-22-1972	Zaffaroni et al.	
	AE	US-3,690,834	09-12-1972	Goldstein et al.	
	AF	US-3,849,420	11-19-1974	Tong	
	AG	US-3,852,434	12-03-1974	Kahan et al.	
	AH	US-3,862,117	01-21-1975	Leverenz	
	AI	US-3,887,329	06-03-1975	Hegar et al.	
	AJ	US-3,966,744	06-29-1976	Goldstein et al.	
	AK	US-3,966,764	06-29-1976	Goldstein et al.	
	AL	US-3,975,384	08-17-1976	Narr et al.	
	AM	US-3,984,411	10-05-1976	Claverie et al.	
	AN	US-4,101,541	07-18-1978	Petitpierre et al.	
	AO	US-4,189,427	02-19-1980	Komorowski	
	AP	US-4,242,507	12-30-1980	Itoh et al.	
	AQ	US-4,267,174	05-12-1981	Berger et al.	
	AR	US-4,275,148	06-23-1981	Endo et al.	
	AS	US-4,397,848	08-09-1983	Bosies et al.	
	AT	US-4,517,183	05-14-1985	Bosies et al.	
	AU	US-5,691,364	11-25-1997	Buckman et al.	
	AV	US-5,849,759	12-15-1998	Arnaiz et al.	
	AW	US-5,948,786	09-07-1999	Fujiwara et al.	

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date/Filing Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
	AX	AU 492126	11-20-1975	Ciba-Geigy AG		
	AY	AT 327605 (w/Eng. abst.)	06-15-2006	Deutsche Telekom AG		
	AZ	BE 829845 (w/counterpart USP 3,984,411)	12-04-1975	Societe Generale de Recherches et d'applications scientifiques		
	BA	BE 868796 (w/counterpart USP 4,267,174)	01-08-1979	Boehringer		
	BB	CH 560197 (w/Eng. abst.)	03-27-1975	Ciba-Geigy AG		
	BC	DE 19602095 (w/Eng. abst.)	07-24-1997	Bayer AG (DE)		
	BD	DE 19737723 (w/Eng. abst.)	02-18-1999	Bayer AG (DE)		
	BE	DE 19962936 (w/Eng. abst.)	06-28-2001	Bayer AG (DE)		

Examiner Signature

/Jeffrey Murray/

Date Considered

02/18/2009

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.M./

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

2 of 22

**Complete if Known**

Application Number	10/541,657
Filing Date	January 14, 2004
First Named Inventor	Robert M. Jones
Art Unit	1624
Examiner Name	To Be Determined

Attorney Docket Number AREN34.US5.PCT

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication/Issue Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
BF	US-5,962,479		10-05-1999	Chen	
BG	US-6,008,234		12-28-1999	Kochanny et al.	
BH	US-6,187,777		02-13-2001	Norman et al.	
BI	US-6,218,431		04-17-2001	Schoen et al.	
BJ	US-6,239,126		05-29-2001	Kelly et al.	
BK	US-6,414,002		07-02-2002	Cheng et al.	
BL	US-6,525,064		02-25-2003	Dellaria et al.	
BM	US-6,545,016		04-08-2003	Dellaria et al.	
BN	US-6,545,017		04-08-2003	Dellaria et al.	
BO	US-6,583,154		06-24-2003	Norman et al.	
BP	US-6,844,351		01-18-2005	Chen et al.	
BQ	US-6,956,047		10-18-2005	Chen et al.	
BR	US-6,239,126		05-29-2001	Kelly et al.	
BS	US-7,083,933		08-01-20066	Prosidion Ltd:	
ON	US-2006/155128		07-13-2006	Jones et al.	

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date/Filing Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
BT	DE 2048375 (w/GB1311956)		04-22-1971	Merck & Co.		
BU	DE 2223644 (w/GB1393993)		11-30-1972	Ciba-Geigy AG		
BV	DE 2341925 (w/Eng. abst.)		03-06-1975	Thomae GmbH		
BW	DE 2356644 (w/USP3,948,914)		05-22-1974	Ciba Geigy AG		
BX	DE 2460238 (w/GB1493380)		07-03-1975	Ciba Geigy AG		
BY	DE 2503136 (w/GB1495665)		07-31-1975	Products Chimiques Ugine Kuhlmann		
BZ	DE 2831850 (w/USP 4,273,870)		02-07-1980	BASF AG		
CA	DE 3334455 (w/Eng. abst.)		09-06-1984	Bayer		
CB	DE 3406329 (w/Eng. abst.)		08-22-1985	Merck & Co.		

Examiner Signature

/Jeffrey Murray/

Date Considered

02/18/2009

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.M./

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet	3	of	22	Attorney Docket Number	AREN34.US5.PCT
-------	---	----	----	------------------------	----------------

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)	Publication Date/Filing Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	CC	DE 3601196 (w/USP4,766,213)	07-23-1987	Merck & Co.		
	CD	EP 0 014 976 (w/USP4,517,183)	09-03-1980	Boehringer		
	CE	EP 0 055 693 (w/USP4,493,726)	07-07-1982	CIBA Geigy AG		
	ON	EP 0 154 190 (w/Eng. abst.)	09-11-1985	Merck Patent Gesellschaft		
	CF	EP 0 283 261	09-21-1988	Zeneca Ltd.		
	CG	EP 0 324 426	07-19-1989	Fuji Photo Film		
	CH	EP 0 518 675	12-16-1992	Merck & Co.		
	CI	EP 0 556 889	08-25-1993	Duphar Int Res		
	CJ	EP 0 565 488 (w/Eng. abst.)	10-13-1993	Ciba Geigy AG		
	CK	EP 0 604 800 (w/Eng. abst.)	07-06-1994	Thomae BMGH		
	CL	EP 0 667 343 (w/Eng. abst.)	08-16-1995	Sandoz Ltd.		
	CM	EP 0 801 059	10-15-1997	Dainippon Pharmaceutical Co		
	CN	EP 0 857 483	08-12-1998	Eli Lilly Co.		
	CO	EP 0 940 387	09-08-1999	Tokyo Tanabe Co.		
	CP	EP 1 074 549	02-07-2001	F. Hoffmann La Roche AG		
	CQ	EP 1 040 831	05-23-2003	Pfizer		
	CR	EP 0 149 088 (w/USP4,643,995)	12-01-1984	Degussa Akt.		
	CS	EP 0 191 603	08-20-1986	Fujisawa Pharma		
	CT	EP 0 193 249	09-03-1986	Duphar		
	CU	EP 1 340 749	09-03-2003	Takada Chemical Industries		
	CV	EP 1 475 094	11-10-2004	Ustav Ex Botan Akademie		
	CW	FR 1551400 (w/USP3,598,801)	12-27-1968	J.R. Geigy AG		
	CX	GB 935595	08-28-1963	Ciba Ltd		
	CY	GB 1311956	03-28-1973	Merck & Co.		
	IU	JP 61-057587 (w/Eng. abst.)	03-24-1986	Shionogi & Co. Ltd.		
	CZ	JP 05-33359 (w/Eng. abst.)	12-17-1993	Mitsui Toatsu Chem		
	DA	JP 07-53546 (w/Eng. abst.)	02-28-1995	Kuraray Co.		
	DB	JP 11-193277 (w/Eng. abst.)	07-21-1999	Nippon Soda Co		
	DC	JP 55-17382 (w/2 Eng. absts.)	02-06-1980	BASF AG		
	DD	JP 2000-038350 (w/Eng. abst.)	02-08-2000	Yoshitomi Pharmaceutical		
	DE	JP 2001-089452 (w/Eng. abst.)	04-04-2001	Sankyo Co		
	DF	JP 2004-269468 (w/Eng. translation)	09-30-2004	Yamanouchi Pharmaceutical		
	DG	JP 2004-269469 (w/Eng. translation)	09-30-2004	Yamanouchi Pharmaceutical		
	DH	NL 6614961 (w/USP3,503,963)	04-24-1967	Ciba Limited		
	DI	NL 6814810 (w/GB1250624)	04-21-1969	Ciba Limited		
	DJ	SU 938 559 (w/Eng. abst.)	11-30-1993	Vsesoyuznyj Ni Khim Farmatsevt		
	DK	WO 94/13677	06-23-1994	Pfizer		

Examiner Signature	/Jeffrey Murray/	Date Considered	02/18/2009
--------------------	------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.<sup>1</sup> Applicant's unique citation designation number (optional).<sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04.<sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).<sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.<sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.M./

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

4 of 22

**Complete if Known**

Application Number	10/541,657
Filing Date	January 14, 2004
First Named Inventor	Robert M. Jones
Art Unit	1624
Examiner Name	To Be Determined

Attorney Docket Number AREN34.US5.PCT

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)	Publication Date/Filing Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
DL	WO 95/33750		12-14-1995	Pfizer		
DM	WO 96/28427		09-19-1996	Berlex Lab		
DN	WO 96/32383 (w/Eng. abst.)		10-17-1996	Dainippon Pharmaceutical		
DO	WO 96/33994 (w/Eng abst.)		10-31-1996	Nippon Soda Co		
DP	WO 96/36613 (w/Eng abst.)		11-21-1996	Nippon Soda Co		
DQ	WO 97/08152 (w/Eng abst.)		03-06-1997	Lonza AG		
DR	WO 97/26252		07-24-1997	FMC Corp.		
DS	WO 97/29109		08-14-1997	Janssen Pharmaceutica, et al.		
DT	WO 97/49706		12-31-1997	Novartis AG		
DU	WO 98/04528		02-05-1998	Bayer Corp.		
DV	WO 98/08846		03-05-1998	Pfizer		
DW	WO 98/08847		03-05-1998	Pfizer		
DX	WO 98/11094		03-19-1998	Schering Akt.		
DY	WO 98/47874		10-29-1998	Janssen Pharmaceutica, et al.		
DZ	WO 98/47903		10-29-1998	Janssen Pharmaceutica, et al.		
EA	WO 99/09026		02-25-1999	Bayer Akt.		
EB	WO 99/51599		10-14-1999	Neurogen Corp		
EC	WO 00/11003		03-02-2000	Du Pont Pharm		
ED	WO 00/27825		05-18-2000	Janssen Pharmaceutica		
EE	WO 00/31068		06-02-2000	Berlex Lab		
EF	WO 00/35875		06-22-2000	Am Home Products		
EG	WO 00/35886		06-22-2000	Axys Pharm Inc		
EH	WO 01/22938		04-05-2001	Janssen Pharmaceutica		
EI	WO 01/23387		04-05-2001	Neurogen Corp et al.		
EJ	WO 01/23388		04-05-2001	Neurogen Corp et al.		
EK	WO 01/25210 (w/Eng. abst.)		04-12-2001	Bayer Akt.		
EL	WO 01/27107		04-19-2001	Bristol Myers Squibb		
EM	WO 01/47887		07-05-2001	Bayer Akt.		
EN	WO 01/49677 (w/Eng. abst.)		07-12-2001	H. Lundbeck A/S		
EO	WO 01/53263		2001-07-26	Pfizer Products		
EP	WO 01/58900 (w/Eng. abst.)		08-16-2001	Hokuriku Seiyaku		

Examiner Signature

/Jeffrey Murray/

Date Considered

02/18/2009

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.M./

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

5 of 22

**Complete if Known**

Application Number	10/541,657
Filing Date	January 14, 2004
First Named Inventor	Robert M. Jones
Art Unit	1624
Examiner Name	To Be Determined

Attorney Docket Number AREN34.US5.PCT

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)	Publication Date/Filing Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
EQ		WO 01/62233	08-30-2001	F. Hoffmann La Roche		
ER		WO 01/85699	11-15-2001	Janssen Pharmaceutica		
ES		WO 02/02549	01-10-2002	Taisho Pharma		
ET		WO 02/06237 (w/Eng. abst.)	01-24-2002	Yamanouchi Pharma		
EU		WO 02/06274	01-24-2002	American Home Prod		
EV		WO 02/070485 (w/Eng. abst.)	09-12-2002	Bayer Akt.		
EW		WO 02/072101	09-19-2002	Bristol-Myers Squibb		
EX		WO 02/19975 (w/Eng abst.)	03-14-2002	Taisho Pharma.		
EY		WO 02/32893	04-25-2002	Schering Corp.		
EZ		WO 02/40451	05-23-2002	Eli Lilly & Co.		
FA		WO 02/40456	05-23-2002	Biovitrum AB		
FB		WO 02/40458 (w/Eng abst.)	05-23-2002	Takeda Chem		
FC		WO 02/40480	05-23-2002	Neurocrine Biosciences		
FD		WO 02/44362 (w/Eng Abst)	06-06-2002	Yamanouchi Pharma		
FE		WO 02/59083	08-01-2002	Smithkline Beecham		
FF		WO 02/98864	12-12-2002	F. Hoffmann La Roche		
FG		WO 02/98878	12-12-2002	Memory Pharm.		
FH		WO 03/000666	01-03-2003	Pfizer Products		
FI		WO 03/002544	01-09-2003	Bristol-Myers Squibb		
FJ		WO 03/026661 (w/Eng. abst.)	04-03-2003	Yamanouchi Pharma		
FK		WO 03/032989	04-24-2003	Boehringer Ingelheim Pharma.		
FL		WO 03/050117	06-19-2003	3M Innovative Properties		
FM		WO 03/057689	07-17-2003	Fujisawa Pharma		
FN		WO 03/077656	09-25-2003	Ciba Specialty Chemicals		
FO		WO 03/087064	10-23-2003	UCB SA		
FP		WO 03/094845	11-20-2003	Bristol Myers Squibb		
FQ		WO 2004/000819	12-31-2003	AstraZeneca AB		
FR		WO 2004/000843	12-31-2003	AstraZeneca AB		
FS		WO 2004/009596	01-29-2004	SmithKline Beecham		
FT		WO 2004/009597	01-29-2004	SmithKline Beecham		
FU		WO 2004/009602	01-29-2004	SmithKline Beecham		
FV		WO 2004/024943 (w/Eng. Abst.)	03-25-2004	Yamanouchi Pharma		
FW		WO 2004/029204	04-08-2004	Merck & Co.		
FX		WO 2004/031189	04-15-2004	Bristol Myers Squibb		

Examiner Signature	/Jeffrey Murray/	Date Considered	02/18/2009
--------------------	------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.M./

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

6 of 22

**Complete if Known**

<i>Application Number</i>	10/541,657
<i>Filing Date</i>	January 14, 2004
<i>First Named Inventor</i>	Robert M. Jones
<i>Art Unit</i>	1624
<i>Examiner Name</i>	To Be Determined
<i>Attorney Docket Number</i>	AREN34.US5.PCT

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date/Filing Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
	FY	WO 2004/035588	04-29-2004	SmithKline Beecham		
	FZ	WO 2004/041164	05-21-2004	Merck & Co.		
	GA	WO 2004/056825	07-08-2004	Syngenta		
	GB	WO 2004/056829	07-08-2004	Syngenta		
	GC	WO 2004/062665	07-29-2004	SB Pharmco et al.		
	GD	WO 2004/065380	08-05-2004	Arena Pharm.		
	GE	WO 2004/074218	09-02-2004	Avanir Pharmaceuticals		
	GF	WO 2004/076413	09-10-2004	Arena Pharm.		
	GG	WO 2004/110000	12-23-2004	Fujisawa Pharmaceutical		
	GH	WO 2005/016894	02-24-2005	Novartis Ag		
	GI	WO 2005/030129	04-07-2005	Merck & Co.		
	GJ	WO 2005/035525	04-21-2005	Vertex Pharm		
	GK	WO 2005/037215	04-28-2005	Massachusetts Inst of Technology		
	GL	WO 2005/046603	05-26-2005	Synta Pharmaceuticals		
	GM	WO 2005/049033	06-02-2005	AstraZeneca AB		
	GN	WO 2005/058315	06-30-2005	Ribapharm Inc		
	GO	WO 2005/061489	07-07-2005	Prosidion Ltd.		
	GP	WO 2005/090348	09-29-2005	Glaxo Group Ltd		
	GQ	WO 2005/100365 (w/Eng. abst.)	10-27-2005	Sankyo Co Ltd.		
	GR	WO 2005/117909	12-15-2005	Exelixis Inc		
	GS	WO 2006/067531	06-29-2006	Prosidion Ltd.		
	GT	WO 2006/067532	06-29-2006	Prosidion Ltd.		
	GU	WO 2006/040966	04-20-2006	Astellas Pharma		
	GV	WO 2006/043490 (w/Eng. Abst)	04-27-2006	Astellas Pharma		
	GW	WO 2006/070208	07-06-2006	Prosidion Ltd.		

Examiner Signature	/Jeffrey Murray/	Date Considered	02/18/2009
--------------------	------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.M./

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

7

of

22

**Complete if Known**

Application Number	10/541,657
Filing Date	January 14, 2004
First Named Inventor	Robert M. Jones
Art Unit	1624
Examiner Name	To Be Determined
Attorney Docket Number	AREN34.US5.PCT

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date/Filing Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)			
	OO	WO 2005/075426	08-18-2005	Glenmark Pharm	
	OP	WO 2005/072530	08-11-2005	Merck	
	OQ	WO 2005/063750	07-14-2005	Boehringer	
	OR	WO 2005/058849	06-30-2005	Glenmark Pharm	
	OS	WO 2005/047297	05-26-2005	Phenomix Corp.	
	OT	WO 2005/042488	05-12-2005	Takeda Pharm	
	OU	WO 2005/040095	05-06-2005	AstraZeneca	
	OV	WO 2005/033099	04-14-2005	Glenmark Pharm	
	OW	WO 2005/030751	04-07-2005	Syrrx	
	OX	WO 2005/030127	04-07-2005	Merck	
	OY	WO 2005/026148	03-24-2005	Syrrx	
	OZ	WO 2005/025554	03-24-2005	Japan Tobacco	
	PA	WO 2005/023762	03-17-2005	Abbott Labs.	
	PB	WO 2005/020920	03-10-2005	Merck	
	PC	WO 03/04498	01-16-2003	Merck	
	PD	WO 00/34241	06-15-2000	Novartis	
	PE	WO 98/19998	05-14-1998	Novartis	
	PF	WO 97/40832	11-06-1997	Hans-Knoll-Inst	
	PG	WO 2005/121121	12-22-2005	Arena Pharm	
	PH	WO 2005/007647	01-27-2005	Arena Pharm	

Examiner Signature	/Jeffrey Murray/	Date Considered	02/18/2009
--------------------	------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.M./

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		<i>Application Number</i>	10/541,657
<i>(Use as many sheets as necessary)</i>		<i>Filing Date</i>	January 14, 2004
Sheet	8	<i>First Named Inventor</i>	Robert M. Jones
		<i>Art Unit</i>	1624
		<i>Examiner Name</i>	To Be Determined
Sheet	8	<i>Attorney Docket Number</i>	AREN34.US5.PCT

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>2</sup>
	GX	ABDALLA et al., "Synthesis and reaction of 3-cyano 2-(1H)-pyridones," <i>Pakistan Journal of Scientific and Industrial Research</i> (1977) 20(3):139-149.		
	GY	ABRAMOVITCH et al., "Solution and flash vacuum pyrolysis of some 2,6-disubstituted β-phenethylsulfonyl azides and of β-styrenesulfonyl azide," <i>J Org Chem</i> (1985) 50:2066-2073.		
	GZ	APPUKKUTTAN et al., "Transition-Metal-Free Sonogashira-Type Coupling Reactions In Water," <i>European Journal Of Organic Chemistry</i> (2003) 24:4713-4716.		
	HA	ARVANITIS et al., "Non-peptide corticotropin-releasing hormone antagonists: syntheses and structure-activity relationships of 2-anilinopyrimidines and -triazines," <i>J Med Chem.</i> (1999) 42(5):805-18.		
	HB	ARVANITIS et al., "Non-peptide corticotropin-releasing hormone antagonists: syntheses and structure-activity relationships of 2-anilinopyrimidines and -triazines," <i>J Med Chem.</i> (1999) Supporting Material, pp. 1-10.		
	HC	ARVANITIS et al., "CRF Ligands via suzuki and negishi couplings of 3-pyridyl boronic acids or halides with 2-benzyloxy-4-chloro-3-nitropyridine," <i>Bioorganic &amp; Medicinal Chemistry Letters</i> (2003) 13(2):289-291.		
	HD	ARVANITIS et al., "Imidazo[4,5-b]pyridines as corticotropin releasing factor receptor ligands," <i>Bioorganic &amp; Medicinal Ch emistry Letters</i> (2003) 13(1):125-128.		
	HE	ARVELA et al., "Rapid, Easy Cyanation of Aryl Bromides and Chlorides Using Nickel Salts in Conjunction with Microwave Promotion," <i>J. Org. Chem.</i> (2003) 68:9122-9125.		
	HF	ARVELA et al., "Rapid cyanation of aryl iodides in water using microwave promotion," <i>Org. Biomol. Chem.</i> (2003) 1:1119-1121.		
	HG	BAINDUR et al., "Solution-Phase Synthesis of a Library of 3,5,7-Trisubstituted 3H-[1,2,3]triazolo[4,5- <i>d</i> ]pyrimidines," <i>J. Comb. Chem.</i> (2003) 5:653-659.		
	HH	BAKKESTUEN et al., "Regioselective N-9 arylation of purines employing arylboronic acids in the presence of Cu(II)," <i>Tetrahedron Letters</i> (2003) 44:3359-3362.		
	HI	BARALDI et al., "An efficient one-pot synthesis of 6-alkoxy-8,9-dialkylpurines via reaction of 5-amino-4-chloro-6-alkylaminopyrimidines with N,N-dimethylalkaneamides and alkoxide ions," <i>Tetrahedron</i> (2002) 58:7607-7611.		
	HJ	BARTA et al., "Synthesis and activity of selective MMP inhibitors with an aryl backbone," <i>Bioorg &amp; Med Chem Ltrs</i> (2000) 10(24):2815-2817.		
	HK	BASKIN et al., "A mild, convenient synthesis of sulfinic acid salts and sulfonamides from alkyl and aryl halides," <i>Tetrahedron Letters</i> (2002) 43:8479-8483.		
Examiner Signature	/Jeffrey Murray/	Date Considered	02/18/2009	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.M./

Substitute for form 1449B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(Use as many sheets as necessary)*

Sheet

9

of

22

<b>Complete if Known</b>	
<i>Application Number</i>	10/541,657
<i>Filing Date</i>	January 14, 2004
<i>First Named Inventor</i>	Robert M. Jones
<i>Art Unit</i>	1624
<i>Examiner Name</i>	To Be Determined
<i>Attorney Docket Number</i>	AREN34.US5.PCT

### NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	HL	BASKIN et al., "An Efficient Copper Catalyst for the Formation of Sulfones from Sulfinic Acid Salts and Aryl Iodides," <i>Org. Lett.</i> (2002) 4(25):4423-4425.	
	HM	BASKIN et al., "An Efficient Copper Catalyst for the Formation of Sulfones from Sulfinic Acid Salts and Aryl Iodides," <i>Org. Lett.</i> (2002) 4(25):4423-4425, Supporting Material #1.	
	HN	BASKIN et al., "An Efficient Copper Catalyst for the Formation of Sulfones from Sulfinic Acid Salts and Aryl Iodides," <i>Org. Lett.</i> (2002) 4(25):4423-4425, Supporting Material #2.	
	HO	BEDFORD et al., "Nonquaternary cholinesterase reactivators. 3. 3(5)-Substituted 1,2,4-oxadiazol-5(3)-aldoximes and 1,2,4-oxadiazole-5(3)-thiocarbohydroximates as reactivators of organophosphonate-inhibited eel and human acetylcholinesterase in vitro," <i>J Med Chem</i> (1986) 29(11):2174-2183.	
	HP	BELLER et al., "Base-catalyzed amination of olefins: an example of an environmentally friendly synthesis of amines," <i>Chemosphere</i> (2001) 43(1):21-26.	
	HQ	BIAGI et al., "4,5,6-trisubstituted 2-phenylpyrimidines and their affinity towards A1 adenosine receptors," <i>Farmaco</i> (1997) 52(1):61-65.	
	HR	BETTI, et al., "Novel 3-Aralkyl-7-(amino-substituted)-1,2,3-triazole[4,5-d]pyrimidines with High Affinity toward A1 Adenosine Receptors," <i>J. Med. Chem.</i> (1998) 41:668-673.	
	HS	BOLDT et al., "Synthesis of 2,4-diaminopyridines," <i>Angewandte Chemie International Edition</i> (1970) 9(5):377.	
	HT	BOMIKA et al., Translation of "Certain reactions of nucleophilic substitution in the 2-chloro-3-cyanopyridine series," <i>Khimiya Geterotsiklicheskikh Soedinenii</i> (1976) (8):1085-1088 (Translated Pages 896-899).	
	HU	BOSCHELLI et al., "1,3,4-Oxadiazole, 1,3,4-thiadiazole, and 1,2,4-triazole analogs of the fenamates: in vitro inhibition of cyclooxygenase and 5-lipoxygenase activities," <i>J Med Chem</i> (1993) 36:1802-1810.	
	HV	BOSWELL et al., "Synthesis of some N-carboxylic acid derivatives of 3-phenoxypprolidines, 4-phenoxyppiperidines, and 3-phenoxyntropamines with muscle relaxant and anticonvulsant activities," <i>J Med Chem</i> (1974) 17(9):1000-1008.	
	HW	BRANCATI et al., "Body Weight Patterns From 20 to 49 Years of Age and Subsequent Risk for Diabetes Mellitus: The Johns Hopkins Precursors Study," <i>Arch Intern Med.</i> (1999) 159:957-963.	
	HX	BROMIDGE et al., "Design of [R-(Z)]-(+)-alpha-(methoxyimino)-1-azabicyclo[2.2.2]octane-3-acetonitrile (SB 202026), a functionally selective azabicyclic muscarinic M1 agonist incorporating the N-methoxy imidoyl nitrile group as a novel ester bioisostere," <i>J Med Chem</i> (1997) 40(26):4265-4280.	
	HY	MUCI et al., "Practical Palladium Catalysts for C-N and C-O Bond Formation," <i>Topics in Current Chemistry</i> (2002) 219:131-209.	
	HZ	BUEHLER et al., "Physiologically active compounds. VI. Cyclic amino thioesters of substituted chloroacetic, benzilic and glycolic acids," <i>J Med Chem</i> (1965) 8:643-647.	

Examiner Signature	<i>/Jeffrey Murray/</i>	Date Considered	02/18/2009
--------------------	-------------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.M./

Substitute for form 1449B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Application Number	10/541,657
(Use as many sheets as necessary)				Filing Date	January 14, 2004
Sheet	10	of	22	First Named Inventor	Robert M. Jones
				Art Unit	1624
				Examiner Name	To Be Determined
				Attorney Docket Number	AREN34.US5.PCT

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
	IA	BULGER et al., "An investigation into the alkylation of 1,2,4-triazole," <i>Tetrahedron Letters</i> (2000) 41:1297-1301.			
	IB	CHAN et al., "Isoquinoline-6-Carboxamides as Potent and Selective Anti-Human Cytomegalovirus (HCMV)Inhibitors," <i>Bioorganic &amp; Medicinal Chemistry Letters</i> (1999) 9:2583-2586.			
	IC	CHEN et al., "Optimization of 3-phenylpyrazolo[1,5-alpha]pyrimidines as potent corticotrophin-releasing factor-1 antagonists with adequate lipophilicity and water solubility," <i>Bioorganic &amp; Medicinal Chemistry Letters</i> (2004) 14:3669-3673.			
	ID	CHEN et al., "Design and Synthesis of a Series of Non-Peptide High-Affinity Human Corticotropin-Releasing Factor 1 Receptor Antagonists," <i>J. Med. Chem.</i> (1996) 39:4358-4360.			
	IE	CHEN et al., "Free Radical Method for the Synthesis of Spiro-Piperidinyl Heterocycles," <i>Tetrahedron Letters</i> (1996) 37(30):5233-5234.			
	IF	CHORVAT et al., "Synthesis, Corticotropin-Releasing Factor Receptor Binding Affinity, and Pharmacokinetic Properties of Triazolo-, Imidazo-, and Pyrrolopyrimidines and -pyridines," <i>J. Med. Chem.</i> (1999) 42:833-848.			
	IG	CLARK et al., "Synthesis and Analgesic Activity of 1,3-Dihydro-3-(Substituted phenyl)imidazo[4,5-b]pyridine-2-ones and 3-(Substituted phenyl)-1,2,3-triazolo(4,5-b)pyridines," <i>J. Med. Chem.</i> (1978) 21(9):965-978.			
	IH	COCUZZA et al., "Use of the Suzuki Reaction for the Synthesis of Aryl-Substituted Heterocycles as Corticotropin-Releasing Hormone (CRH) Antagonists," <i>Bioorganic &amp; Medicinal Chemistry Letters</i> (1999) 9:1063-1066.			
	II	COHEN et al., "The Preparation and Properties of 6-Halomethylpurines," <i>Div. of Nucleoprotein Chemistry, Sloan-Kettering Institute for Cancer Research, and Sloan Kettering Div. Grad. School of Med. Sci., Cornell Univ. Med. College</i> (1962) 27:3545-3549.			
	IJ	COLANDREA et al., "Synthesis and regioselective alkylation of 1,6- and 1,7-naphthyridines," <i>Tetrahedron Letters</i> (2000) 41:8053-8057.			
	IK	COLLIER et al., "Radiosynthesis and in-vivo evaluation of the pseudopeptide $\delta$ -opioid antagonist [ <sup>125</sup> I]-ITIPP( $\Psi$ )," <i>J. Labeled Compd. Radiopharm.</i> , (1999) 42(Suppl. 1):S264-S266.			
	IL	COSSEY et al., "Amide-acid chloride adducts. VI. Pyridines and pyridinium salts from cyanoacetamides," <i>Australian Journal of Chemistry</i> (1976) 29(5):1039-1050.			
	IM	CRYAN et al., "Behavioral characterization of the novel GABAB receptor-positive modulator GS39783 (N,N'-dicyclopentyl-2-methylsulfanyl-5-nitropyrimidine-4,6-diamine): Anxiolytic-like activity without side effects associated with baclofen or benzodiazepines," <i>Journal of Pharmacology and Experimental Therapeutics</i> (2004) 310(3):952-963			
	IN	DAI et al., "The first general method for palladium-catalyzed Negishi cross-coupling of aryl and vinyl chlorides: use of commercially available Pd(P(t-Bu) <sub>3</sub> ) <sub>2</sub> as a catalyst," <i>J Am Chem Soc</i> (2001) 123(12):2719-2724.			

Examiner Signature	/Jeffrey Murray/	Date Considered	02/18/2009
--------------------	------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.88. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.M./

Substitute for form 1449B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<i>Application Number</i>	10/541,657
Sheet	11	of	22	<i>Filing Date</i>	January 14, 2004
				<i>First Named Inventor</i>	Robert M. Jones
				<i>Art Unit</i>	1624
				<i>Examiner Name</i>	To Be Determined
				<i>Attorney Docket Number</i>	AREN34.US5.PCT

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>2</sup>
	IO	DESIMONI et al., "Polynuclear Isoxazole Types-I – Isoxazolo[4,5-d]Pyrimidines," <i>Tetrahedron</i> (1967) 23:675-680.			
	IP	DEVITA et al., "Identification and initial structure-activity relationships of a novel non-peptide quinolone GnRH receptor antagonist," <i>Bioorg &amp; Med Chem Ltrs</i> (1999) 9(17):2615-2620.			
	IQ	DI BRACCIO et al., "Synthesis and preliminary pharmacological examination of 2,4-disubstituted N,N-dialkyl-1,8-naphthyridine-3-carboxamides," <i>Farmaco</i> (1989) 44(9):865-881.			
	IR	DZIERBA et al., "Synthesis, Structure-Activity Relationships, and in Vivo Properties of 3,4-Dihydro-1H-pyrido[2,3-b]pyrazin-2-ones as Corticotropin-Releasing Factor-1 Receptor Antagonists," <i>Journal of Medicinal Chemistry</i> (2004) 47(23):5783-5790.			
	IS	EICHER et al., "Reaction of triafulvenes with isonitriles. A simple synthesis of diphenyl-substituted functionalized cyclobutene derivatives and related products," <i>Synthesis</i> (1987) (7):619-626.			
	IT	ESCHER et al., "Cyclopentylamine Substituted Triazolo[4,5-D]Pyrimidine: Implications for Binding to the Adenosine Receptor," <i>Tetrahedron Letters</i> (1991) 32(29):3583-3584.			
	IV	GANGLOFF et al., "Synthesis of 3,5-disubstituted-1,2,4-oxadiazoles using tetrabutylammonium fluoride as a mild and efficient catalyst," <i>Tetrahedron Letters</i> (2001) 42:1441-1443.			
	IW	GILLIGAN et al., "Corticotropin-releasing factor antagonists: Recent advances and exciting prospects for the treatment of human diseases," <i>Current Opinion in Drug Discovery &amp; Development</i> (2004) 7(4):487-497.			
	IX	GILLIGAN, et al., "Corticotropin Releasing Factor (CRF) Receptor Modulators" Progress and Opportunities for New Therapeutic Agents," <i>J. Med. Chem.</i> (2000) 43(9):1641-1660.			
	IY	GOLDNER et al., "Die Darstellung 2,9-, 2,6,9- und 6,9-substituierter Purine," <i>Journal fuer Praktische Chemie (Leipzig)</i> (1961) 12:242-252.			
	IZ	GINER-SOROLLA et al., "The Synthesis and Properties of 6-Mercaptomethylpurine and Derivatives," <i>Cornell University Medical College</i> (1965) 8:667-672.			
	JA	GOMTSYAN et al., "Design, synthesis, and structure-activity relationship of 6-alkynylpyrimidines as potent adenosine kinase inhibitors," <i>J Med Chem.</i> (2002) 45(17):3639-3648.			
	JB	HAMADA et al., "An improved synthesis of arylsulfonyl chlorides from arylhalides," <i>Synthesis</i> (1986) pp. 852-854.			
	JC	HE et al., "4-(1,3-Dimethoxyprop-2-ylamino)-2,7-dimethyl-8-(2,4-dichlorophenyl)-pyrazolo[1,5-a]-1,3,5-triazine: A Potent, Orally Bioavailable CRF1 Receptor Antagonist," <i>J. Med. Chem.</i> (2000) 43:449-456.			

Examiner Signature	/Jeffrey Murray/	Date Considered	02/18/2009
--------------------	------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered.  
 Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.  
 This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.M./

Substitute for form 1449B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Application Number</b> 10/541,657 <b>Filing Date</b> January 14, 2004 <b>First Named Inventor</b> Robert M. Jones <b>Art Unit</b> 1624 <b>Examiner Name</b> To Be Determined	
Sheet	12	of	22	<b>Attorney Docket Number</b> AREN34.US5.PCT	

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>2</sup>
	JD	HECHT et al., "On the "activation" of cytokins*,," <i>J of Biological Chemistry</i> (1975) 250(18):7343-7351.		
	JE	HERSPERGER et al., "Palladium-Catalyzed Cross-Coupling Reactions for the Synthesis of 6,8-Disubstituted 1,7-Naphthyridines: A Novel Class of Potent and Selective Phosphodiesterase Type 4D Inhibitors," <i>J. Med. Chem.</i> (2000) 43:675-682.		
	*JF	HIGUCHI et al., "Pro-drugs as novel delivery systems," <i>A.C.S. Symposium Series</i> , Vol. 14 (1987).		
	JG	HILL et al., "Environmental contributions to the obesity epidemic," <i>Science</i> (1998) 280(5368):1371-4.		
	JH	HOCEK et al., "An Efficient Synthesis of 2-Substituted 6-Methylpurine Bases and Nucleosides by Fe- or Pd-Catalyzed Cross-Coupling Reactions of 2,6-Dichloropurines," <i>J. Org. Chem.</i> (2003) 68:5773-5776.		
	JI	HUANG et al., "Synthesis and Antiplatelet Activity of Phenyl Quinolones," <i>Bioorganic &amp; Medicinal Chemistry</i> (1998) 6:1657-1662.		
	JJ	BERGE et al., "Pharmaceutical Salts," <i>Journal of Pharmaceutical Sciences</i> (1977) 66(1):1-19.		
	JK	JIA, et al., "Design, Synthesis and Biological Activity of Novel Non-Amidine Factor Xa Inhibitors. Part 1: P1 Structure-Activity Relationships of the Substituted 1-(2-Naphthyl)-1H-pyrazole-5-carboxylamides," <i>Bioorganic &amp; Medicinal Chemistry Letters</i> (2002) 12:1651-1655.		
	JL	JOGIE et al., "Unusual protein-binding specificity and capacity of aza-arenophilic gels," <i>Journal of Molecular Recognition</i> (1998) 11:261-262.		
	JM	KAWASE et al., " $\alpha$ -trifluoromethylated acyloins induce apoptosis in human oral tumor cell lines," <i>Bioorg &amp; Med Chem Ltrs</i> (1999) 9(21):3113-3118.		
	JN	KELLY et al., "A Synthesis of Aaptamine," <i>Tetrahedron</i> (1985) 41(15):3033-3066.		
	JO	KELLEY et al., "Benzodiazepine receptor binding activity of 8-substituted-9-(3-substituted-benzyl)-6-(dimethylamino)-9H-purines," <i>J Med Chem</i> (1990) 33(1):196-202.		
Examiner Signature		/Jeffrey Murray/		Date Considered
				02/18/2009

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO				<b>Complete if Known</b>	
				<i>Application Number</i>	10/541,657
				<i>Filing Date</i>	January 14, 2004
				<i>First Named Inventor</i>	Robert M. Jones
				<i>Art Unit</i>	1624
				<i>Examiner Name</i>	To Be Determined
Sheet	13	of	22	<i>Attorney Docket Number</i>	
<b>NON PATENT LITERATURE DOCUMENTS</b>					

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				T <sup>2</sup>
	JP	KEMPSON et al., "Fused pyrimidine based inhibitors of phosphodiesterase 7 (PDE7): synthesis and initial structure-activity relationships," <i>Bioorganic &amp; Medicinal Chemistry Letters</i> (2005) 15:1829-1833.				
	JQ	KHATTAB et al., "Quinolines with heteroatom substituents in position 2 and 4. Nucleophilic substitution of 2,4-dichloro-3-phenylquinolines," <i>ACH - Models in Chemistry</i> (1994) 131(3-4):521-527.				
	JR	KLOETZER et al., "Chlorierende formylierungsreaktionen an pyrimidinen," <i>Monatshefte fuer Chemie</i> , (1965) 96(5):1567-1572.				
	JS	KOTIAN et al., "Synthesis, ligand binding, and quantitative structure-activity relationship study of 3β-(4'-substituted phenyl)-2β-heterocyclic tropanes: evidence for an electrostatic interaction at the 2β -position," <i>J Med Chem</i> (1996) 39(14):2753-2763.				
	JT	KRAUZE et al., "Derivatives of 3-cyano-6-phenyl-4-(3'-pyridyl)-pyridine-2(1H)-thione and their neurotropic activity," <i>European Journal of Medicinal Chemistry</i> (1999) 34(4):301-310.				
	JU	KRAUZE et al., "Synthesis of 3-oxoisothiazolo[5,4-b]pyridines," <i>Khimiya Geterotsiklicheskikh Soedinenii</i> (1982) (4):508-512.				
	JV	KUMEGAI et al., "Synthesis, SAR and biological activities of CRH1 Receptor: Novel 3- or 4-carbamoyl-1,2,5,6-tetrahydropyridinopyrrolopyrimidine derivative," 4 <sup>th</sup> ACS National Meeting, August 18-22, 2002, Boston, MA. Poster #259.				
	JW	LAI et al., "A one-pot method for the efficient conversion of aryl- and acyl-substituted methyl alcohols into chlorides," <i>Synthetic Communications</i> (2003) 33(10):1727-1732.				
	JX	LANIER et al., "Small molecule corticotrophin-releasing factor antagonists," <i>Expert Opinion</i> (2002) 12(11):1619-1630.				
	JY	LEADBEATER et al., "First Examples Of Transition-Metal Free Sonogashira-Type Couplings," <i>Organic Letters</i> (2003) 5(21):3919-3922				

Examiner Signature	/Jeffrey Murray/	Date Considered	02/18/2009
--------------------	------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		<i>Application Number</i>	10/541,657
(Use as many sheets as necessary)		<i>Filing Date</i>	January 14, 2004
Sheet	14	of	22
		<i>First Named Inventor</i>	Robert M. Jones
		<i>Art Unit</i>	1624
		<i>Examiner Name</i>	To Be Determined
		<i>Attorney Docket Number</i>	AREN34.US5.PCT

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>2</sup>
	JZ	LEADBEATER et al., "Transition-metal free sonogashira-type couplings," <i>Department of Chemistry, King's College London, Supplementary Information</i> , pp. S1-S4.		
	KA	LEE et al., "Synthesis and biological evaluation of cltocine analogues as adenosine kinase inhibitors," <i>Bioorg &amp; Med Chem Lett</i> (2001) 11(18):2419-2422.		
	KB	LEESE et al., "Potential antipurines. II. Synthesis of 6- and 9-substituted purines and 8-azapurines," <i>Journal of the Chemical Society</i> (1958) 4107-4110.		
	KC	LE BAS et al., "Radioiodinated analogs of EP 00652218 for the exploration of the tachykinin NK1 receptor by spect," <i>J. Labeled Compd. Radiopharm.</i> (2001) 44:S280-S282.		
	KD	LE STUNFF et al., "Early changes in postprandial insulin secretion, not in insulin sensitivity, characterize juvenile obesity," <i>Diabetes</i> (1989) 43:696-702.		
	KE	LIN, et al., "Synthesis and Antitumor Activity of Halogen-Substituted 4-(3,3-Dimethyl-1-triazeno)quinolines," <i>J. Med. Chem.</i> (1978) 21(3):268-272.		
	KF	LITVAK et al., "Polynucleotides and Their Components in the Processes of Aromatic Nucleophilic Substitution: II.1 Nucleophilic Modification of 3',5'-Bis-O-(α,β,α',β'-tetrafluoropyrid-γ-yl)thymidine," <i>Russian Journal of Bioorganic Chemistry</i> (2004) 30(4):337-343.		
	KG	LITVINOV et al., "Naphthyridines. Structure, physicochemical properties and general methods of synthesis," <i>Russian Chemical Reviews</i> (2000) 69(3):201-220.		
	KH	LOUPY et al., "Easy and efficient SNAr Reactions on halopyridines in solvent free conditions," <i>Heterocycles</i> (1991) 32(10):1947-1952.		
	KI	LUO et al., "Microwave-assisted synthesis of aminopyrimidines," <i>Tetrahedron Letters</i> (2002) 43:5739-5742.		
	KJ	GROGER "Moderne methoden der Suzuki-kreuzkupplung: die langerwarteten universellen synthesevarianten mit arylchloriden," <i>J Prakt Chem</i> (2000) 342(4):334-339.		
	KK	MA, et al. "Mild Method for Ullmann Coupling Reaction of Amines and Aryl Halides," <i>Organic Letters</i> (2003) 5(14):2453-2455.		
	KL	MACCHIA et al., "New N-n-propyl-substituted 3-aryl- and 3-cyclohexylpiperidines as partial agonists at the D4 dopamine receptor," <i>J Med Chem</i> (2003) 46(1):161-168.		
	KM	MACKMAN et al., "2-(2-Hydroxy-3-alkoxyphenyl)-1H-benzimidazole-5-carboxamidine derivatives as potent and selective urokinase-type plasminogen activator inhibitors," <i>Bioorganic &amp; Medicinal Chemistry Letters</i> (2002) 12(15):2019-2022.		

Examiner Signature	/Jeffrey Murray/	Date Considered	02/18/2009
--------------------	------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.M./

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

15

of

22

### Complete if Known

Application Number	10/541,657
Filing Date	January 14, 2004
First Named Inventor	Robert M. Jones
Art Unit	1624
Examiner Name	To Be Determined

Attorney Docket Number AREN34.US5.PCT

### NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	KN	MAJEEED, et al, "Stannylation Reactions and Cross-Couplings in Pyrimidines," <i>Tetrahedron</i> (1989) 45(4):993-1006.	
	KO	MATSUI et al., "Highly potent inhibitors of TNF- $\alpha$ production. Part II: metabolic stabilization of a newly found chemical lead and conformational analysis of an active diastereoisomer," <i>Bioorg Med Chem.</i> (2002) 10(12):3787-805.	
	KP	MATSUNO et al., "Potent and selective inhibitors of platelet-derived growth factor receptor phosphorylation. 3. Replacement of quinazoline moiety and improvement of metabolic polymorphism of 4-[4-(N-substituted (thio)carbamoyl)-1-piperazinyl]-6,7-dimethoxyquinazoline derivatives," <i>J Med Chem</i> (2003) 46(23):4910-4925.	
	KQ	MESGUICHE et al., "4-Alkoxy-2,6-diaminopyrimidine derivatives: inhibitors of cyclin dependent kinases 1 and 2," <i>Bioorganic &amp; Medicinal Chemistry Letters</i> (2003) 13(2):217-222.	
	KR	METZGER et al., "Einstufensynthese von 2,4-Bis(sec-alkylamino-6-halogen-3-pyridincarbonitrilen**)," <i>Liebigs Annalen der Chemie</i> (1980) (6):946-953.	
	KS	MITTELBACH et al., "Syntheses with nitriles. 60. Preparation of 4-amino-5-cyano-6-phenylpyrimidines from 2-amino-1,1-dicyano-2-phenylethene," <i>Journal of Heterocyclic Chemistry</i> (1980) 17(7):1385-1387.	
	KT	MIYASHITA et al., "Preparation of Heterarenecarbonitriles by Reaction of Haloheteroarenes with Potassium Cyanide Atalyzed by Sodium p-Toluenesulfinate," <i>Heterocycles</i> (1994) 39(1):345-350.	
	KU	MOHAN et al., "Solid-phase synthesis of N-substituted amidinophenoxy pyridines as factor Xa inhibitors," <i>Bioorganic &amp; Medicinal Chemistry Letters</i> (1998) 8(14):1877-1882.	
	KV	MOMBEREAU et al., "Genetic and Pharmacological Evidence of a Role for GABAB Receptors in the Modulation of Anxiety- and Antidepressant-Like Behavior," <i>Neuropsychopharmacology</i> (2004) 29(6):1050-1062.	
	KW	MONGIN et al., "Advances in the directed metallation of azines and diazines (pyridines, pyrimidines, pyrazines, pyridazines, quinolines, benzodiazines and carbolines). Part 1: Metallation of pyridines, quinolines and carbolines," <i>Tetrahedron</i> (2001) 57(19):4059-4090.	
	KX	MONTGOMERY et al., "Isonucleosides. I. Preparation of methyl 2-deoxy-2-(purin-9-yl)arabinofuranosides and methyl 3-deoxy-3-(purin-9-yl)xylofuranosides," <i>Journal of Organic Chemistry</i> (1975) 40(13):1923-1927.	
	KY	MORIMOTO et al., "Potent and selective ET-A antagonists. 1. Syntheses and structure-activity relationships of N-(6-(2-(aryloxy)ethoxy)-4-pyrimidinyl)sulfonamide derivatives," <i>J Med Chem</i> (2001) 44(21):3355-3368.	

Examiner Signature

/Jeffrey Murray/

Date Considered

02/18/2009

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 600. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.M./

Substitute for form 1449B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Application Number	10/541,657
(Use as many sheets as necessary)				Filing Date	January 14, 2004
Sheet	16	of	22	First Named Inventor	Robert M. Jones
				Art Unit	1624
				Examiner Name	To Be Determined
				Attorney Docket Number	AREN34.US5.PCT

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	KZ	MOSCHITSKII et al., Translation of "Reaction of 2,3,5,6-tetrachloro-4-pyridyl-vinyl sulfone with nuleophilic agents," <i>Khimiya Geterotsiklichesikh Soedinenii</i> (1972) pp. 1634-1637, (Translated Pages 1482-1485).	
	LA	MULLER et al., "7-Deaza-2-phenyladenines: Structure-Activity Relationships of Potent A1 Selective adenosine Receptor Antagonists," <i>J. Med. Chem.</i> (1990) 33:2822-2828	
	LB	NAKAZATO et al., "Synthesis, SAR and biological activities of CRH1 Receptor: Novel 3- or 4-carbamoyl-1,2,5,6-tetrahydropyridinoquinoline derivative," 24 <sup>th</sup> ACS National Meeting, August 18-22, 2002, Boston, MA. Poster #258.	
	LC	NAKAZATO et al., "Design, synthesis and structure-affinity relationships of 4-methylideneperipiperidine and 4-aryl-1,2,3,6-tetrahydropyridine derivatives as corticotropin-releasing factor receptor antagonists," <i>Bioorganic &amp; Medicinal Chemistry</i> (2000) 8(5):1183-1193.	
	LD	NESI et al., "New Disfunctionalized 4-Nitroisoxazoles from Alpha-Nitroacetophenone Oxime," <i>Heterocycles</i> (1985) 23(6):1465-1469.	
	LE	NICEWONGER et al., "Microwave-assisted acylation of 7-amino-5-aryl-6-cyanopyrido[2,3-d]pyrimidines," <i>Molecular Diversity</i> (2003) 7(2-4):247-252.	
	LF	NORMAN et al., "Structure -activity relationships of a series of pyrrolo(3,2-d) pyrimidine derivatives and related compounds as neuropeptide Y5 receptor antagonists" <i>J. Med. Chem.</i> (2000) 43(22):4288-4312.	
	LG	NORMAN et al., "Structure -activity relationships of a series of pyrrolo(3,2-d) pyrimidine derivatives and related compounds as neuropeptide Y5 receptor antagonists" <i>J. Med. Chem.</i> (2000) 43(22):4288-4312, JM000269T, Supplemental Material, pages 1-11.	
	LH	OLESEN et al., "The use of bioisosteric groups in lead optimization," <i>Current Opinion in Drug Discovery &amp; Development</i> (2001) 4(4):471-478.	
	LI	PARLOW et al., "Design, synthesis, and crystal structure of selective 2-pyridone tissue factor VIIa inhibitors," <i>J Med Chem</i> (2003) 46(22):4696-4701.	
	LJ	PAULSEN et al., "Darstellung von Bausteinen zur Synthese carbocyclischer furanose-analoga," <i>Chemische Berichte</i> (1981) 114(1):346-358.	
	LK	PEDERSON, "The impact of obesity on the pathogenesis of non-insulin-dependent diabetes mellitus: a review of current hypotheses," <i>Diab. Metab. Rev.</i> , (1989) 5(6):495-509.	
Examiner Signature	/Jeffrey Murray/	Date Considered	02/18/2009

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		<i>Application Number</i>	10/541,657
(Use as many sheets as necessary)		<i>Filing Date</i>	January 14, 2004
Sheet 17 of 22		<i>First Named Inventor</i>	Robert M. Jones
		<i>Art Unit</i>	1624
		<i>Examiner Name</i>	To Be Determined
		<i>Attorney Docket Number</i>	AREN34.US5.PCT

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>2</sup>
	LL	PERRY et al., "Prospective study of risk factors for development of non-insulin dependent diabetes in middle aged British men," <i>BMJ</i> (1995) 310(6979):560-4.		
	LM	PHILLIPS et al., "Discovery of N-[2-[5-[Amino(imino)methyl]2-hydroxyphenoxy]-3,5-difluoro-6-[3-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenoxy]pyridine-4-yl]-N-methylglycine(ZK-807834): A Potent, Selective, and Orally Active Inhibitor of the Blood Coagulation Enzyme Factor Xa," <i>J. Med. Chem.</i> (1998) 41(19):3557-3562.		
	LN	POMORSKI "Synthesis of Acids, Derivatives of 4-Hydroxy-1,5-Naphthyridine," <i>Roczniki Chemii, Ann. Soc. Chim. Polonorum</i> (1974) 48:321-325.		
	LO	POTENZA et al., "A rapid quantitative bioassay for evaluating the effects of ligands upon receptors that modulate cAMP levels in a melanophore cell line," <i>Pigment Cell Res.</i> (1992) 5(6):372-8.		
	LP	PRASAD, et al., "Convenient Methods for the Reduction of Amides, Nitriles, Carboxylic Esters, Acids and Hydroboration of Alkenes Using NaBH <sub>4</sub> /LiSystem," <i>Tetrahedron</i> (1992) 48(22):4623-4628.		
	LQ	PRESS et al., "Synthesis and SAR of 6-Substituted Purine Derivatives as Novel Selective Positive Inotropes," <i>J. Med. Chem.</i> (1992) 35(24):4509-4515.		
	LR	QUINTELA et al., "6-Dimethylamino 1H-Pyrazolo[3,4-d]pyrimidine Derivatives as New Inhibitors of Inflammatory Mediators in Intact Cells," <i>Bioorganic &amp; Medicinal Chemistry</i> (2003) 11:863-868.		
	LS	QUINTELA et al., "Pyrazolopyrimidines: synthesis, effect on histamine release from rat peritoneal mast cells and cytotoxic activity," <i>Eur. J. Med. Chem.</i> (2001) 36:321-332.		
	LT	RAM et al., "Chemotherapeutic agents. Part XXII. Synthesis of $\pi$ -deficient pyrimidines as leishmanicides," <i>Indian Journal of Chemistry, Section B</i> (1991) 30B(10):962-965.		
	LU	REED et al., "In-vivo and in-vitro models of type 2 diabetes in pharmaceutical drug discovery," <i>Diabetes Obes Metab.</i> (1999) 1(2):75-86.		
	LV	REHWALD et al., "Syntheses of thieno[2,3-d]pyrimidines and aminopyrimidines from 2-alkoxy-5-cyano-4-thioxopyrimidine intermediates," <i>Heterocycles</i> (1998) 48(6):1157-1167.		
	LW	Remington's <i>Pharmaceutical Sciences</i> , 17 <sup>th</sup> Ed., (1985), Mack Publishing Company, Easton, PA, p. 1418-1419.		

Examiner Signature	/Jeffrey Murray/	Date Considered	02/18/2009
--------------------	------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		Application Number	January 14, 2004
(Use as many sheets as necessary)		Filing Date	July 6, 2006
Sheet	18	of	22
		First Named Inventor	Robert M. Jones
		Art Unit	1624
		Examiner Name	To Be Determined
		Attorney Docket Number	AREN34.US5.PCT

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	*LX	<i>Remington's Pharmaceutical Sciences</i> , 16 <sup>th</sup> Ed., (1980), Mack Publishing Company, Easton, PA.	
	LY	<i>REWCastle, et al., "Tyrosine Kinase Inhibitors. 10. Isomeric 4-[3-Bromophenyl]amino]pyrido[d]pyrimidines are Potent ATP Binding Site Inhibitors of the Tyrosine Kinase Function of the Epidermal Growth Factor Receptor," J. Med. Chem. (1996) 39:1823-1835.</i>	
	LZ	<i>RAFFEL et al., "Diabetes Mellitus," Principles And Practice Of Medical Genetics, 3<sup>rd</sup> Ed. 1:1401-1440 (1996).</i>	
	MA	<i>ROBERTS et al., "Peroxy-acid oxidation of N,N-disubstituted aminotetrafluoro-, amino-3-chlorotrifluoro-, and amino-3,5-dichlorodifluoro-pyridines," Journal of the Chemical Society [Section] C: Organic (1969) (11):1485-1491.</i>	
	MB	<i>ROBERTS et al., "Polychloroaromatic compounds. I. Oxidation of pentachloropyridine and its N,N-disubstituted amino derivatives with peroxyacids," Journal of the Chemical Society [Section] C: Organic (1968) (12):1537-1541.</i>	
	MC	<i>ROBINS, et al., "Potential Purine Antagonists. IV. Synthesis of Some 9-Methyl-6-substituted-purines," (1957) 79:490-494.</i>	
	MD	<i>ROBEV et al., "4-Cyclopropylamino- and 4-cyclobutylamino derivatives of some aryl-substituted 5-cyanopyrimidines," Doklady Bolgarskoj Akademii Nauk (1981) 34(12):1677-1680.</i>	
	*ME	<i>ROCHE, Bioreversible Carriers in Drug Design, ed., American Pharmaceutical Association and Pergamon Press (1987).</i>	
	MF	<i>ROTWEIN et al., "Polymorphism in the 5' flanking region of the human insulin gene: a genetic marker for non-insulin-dependent diabetes," N Engl J Med. (1983) 308(2):65-71.</i>	
	MG	<i>SHOWELL et al., "Tetrahydropyridyloxadiazoles: semirigid muscarinic ligands," J Med Chem (1991) 34(3):1086-1094.</i>	
	MH	<i>SILHAR et al., "Facile and Efficient Synthesis of 6-(Hydroxymethyl)purines," Org. Lett. (2004) 6(19):3225-3228.</i>	
	MI	<i>SMITH et al., "Effects of positive allosteric modulators of the GABAB receptor on cocaine self-administration in rats," Psychopharmacology (2004) 173(1-2):105-111.</i>	
	MJ	<i>SILVESTRI et al., "Novel indolyl aryl sulfones active against HIV-1 carrying NNRTI resistance mutations: synthesis and SAR studies," J Med Chem (2003) 46(12):2482-2493.</i>	
	MK	<i>STEENSMA et al., "A novel method for the synthesis of aryl sulfones," Tetrahedron Ltrs (2001) 42:2281-2283.</i>	

Examiner Signature	/Jeffrey Murray/	Date Considered	02/18/2009
--------------------	------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.M./

Substitute for form 1449B/PTO			<b>Complete if Known</b>		
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>			<i>Application Number</i>	10/541,657	
<i>(Use as many sheets as necessary)</i>			<i>Filing Date</i>	January 14, 2004	
Sheet	19	of	22	<i>First Named Inventor</i>	Robert M. Jones
			<i>Art Unit</i>	1624	
			<i>Examiner Name</i>	To Be Determined	
			<i>Attorney Docket Number</i>	AREN34.US5.PCT	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	ML	STERNFELD et al., "Synthesis and serotonergic activity of 3-[2-(pyrrolidin-1-yl)ethyl]indoles: potent agonists for the h5-HT1D receptor with high selectivity over the h5-HT1B receptor," <i>J Med Chem</i> (1999) 42(4):677-690.	
	MM	STRUPCZEWSKI et al., "Synthesis and neuroleptic activity of 3-(1-substituted-4-piperidinyl)-1,2-benzisoxazoles," <i>J Med Chem</i> (1985) 28(6):761-769.	
	MN	SUAMI et al., "Nucleoside analogs. I. Synthesis of 1,3-dihydroxy-2-(6-substituted-9-purinyl)cyclohexane," <i>Journal of Heterocyclic Chemistry</i> (1969) 6(5):663-665.	
	MO	SUGIMOTO et al., "Preparation of Nitrogen-Containing $\pi$ -Deficient Heteroaromatic Grignard Reagents: Oxidative Magnesiation of Nitrogen-Containing $\pi$ -Deficient Halogenoheteroaromatics Using Active Magnesium," <i>J. Org. Chem.</i> (2003) 68:2054-2057.	
	MP	SUGIMOTO et al., "Lithiation of 1H-Pyrazolo[3,4-d]pyrimidine Derivative Using Lithium Alkanetellurolate," <i>Tetrahedron Letters</i> (1999) 40:2139-2140.	
	MQ	TERASHIMA et al., "Inhibition of human O6-alkylguanine-DNA alkyltransferase and potentiation of the cytotoxicity of chloroethylnitrosourea by 4(6)-(benzyloxy)-2,6(4)-diamino-5-(nitro or nitroso)pyrimidine derivatives and analogues," <i>J Med Chem</i> (1998) 41(4):503-508.	
	MR	THOMPSON et al., "N <sup>6</sup> ,9-Disubstituted Adenines: Potent, Selective Antagonists at the A1 Adenosine Receptor," <i>J. Med. Chem.</i> (1991) 34:2877-2882.	
	MS	THOMPSON et al., "Synthesis and evaluation of 6-(dibromomethyl)-5-nitropyrimidines as potential antitumor agents," <i>J Med Chem</i> (1997) 40(5):766-770.	
	MT	TURCK et al., "Advances in the directed metallation of azines and diazines (pyridines, pyrimidines, pyrazines, pyridazines, quinolines, benzodiazines and carbolines). Part 2: Metallation of pyrimidines, pyrazines, pyridazines and benzodiazines," <i>Tetrahedron</i> (2001) 57(21):4489-4505.	
	MU	URGAONKAR et al., "Pd/P(i-BuNCH <sub>2</sub> CH <sub>2</sub> ) <sub>2</sub> N: an efficient catalyst for Suzuki cross-coupling of aryl bromides and chlorides with arylboronic acids," <i>Tetrahedron Letters</i> (2002) 43(49):8921-8924.	
	MV	URWYLER et al., " <i>N,N'</i> -Dicyclopentyl-2-methylsulfanyl-5-nitro-pyrimidine-4,6-diamine (GS39783) and structurally related compounds: Novel allosteric enhancers of $\gamma$ -aminobutyric acidB receptor function," <i>Journal of Pharmacology and Experimental Therapeutics</i> (2003) 307(1):322-330.	

Examiner Signature	/Jeffrey Murray/	Date Considered	02/18/2009
--------------------	------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.M./

Substitute for form 1449B/PTO			<b>Complete if Known</b>		
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>			<i>Application Number</i>	10/541,657	
(Use as many sheets as necessary)			<i>Filing Date</i>	January 14, 2004	
Sheet	20	of	22	<i>First Named Inventor</i>	Robert M. Jones
			<i>Art Unit</i>	1624	
			<i>Examiner Name</i>	To Be Determined	
			<i>Attorney Docket Number</i>	AREN34.US5.PCT	

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>2</sup>
	MW	VAUGHAN et al., "The Reformatsky Reaction. I. Zinc and Ethyl Alpha-Bromoisobutyrate," <i>Dept. of Chem., The Univ. of Michigan, Ann Arbor, MI</i> , (1964) 30:1790-1795.		
	MX	VICE, et al., "Concise Formation of 4-Benzyl Piperidines and Related Derivatives Using a Suzuki Protocol," <i>J. Org. Chem.</i> (2001) 66:2487-2492.		
	MY	VICE, et al., "Concise Formation of 4-Benzyl Piperidines and Related Derivatives Using a Suzuki Protocol," <i>J. Org. Chem.</i> (2001) 66:2487-2492, Supporting Information, pp. S1-S32		
	MZ	WANG et al., "Improving the oral efficacy of CNS drug candidates: discovery of highly orally efficacious piperidinyl piperidine M2 muscarinic receptor antagonists," <i>J Med Chem</i> (2002) 45(25):5415-5418.		
	NA	WELLS et al., "Regioselective nucleophilic substitutions of fluorobenzene derivatives," <i>Tetrahedron Letters</i> (1996) 37(36):6439-6442.		
	NB	WERBEL et al., "Synthesis and antimalarial effects of 5,6-dichloro-2-[(4-[[4-(diethylamino) 1-methylbutyl]amino [[-6-methyl-2-pyrimidinyl]amino] benzimidazole and related benzimidazoles and 1,2-Imidazo[4,5-b] pyridines," <i>J. Het. Chem</i> (1973) Vol. 10, 363-382.		
	NC	WILSON et al., "Microwave-assisted synthesis of 2-aminoquinolines," <i>Tetrahedron Letters</i> (2002) 43(4):581-583.		
	ND	WOLFE et al., "Scope and limitations of the Pd/BINAP-catalyzed amination of aryl bromides," <i>J Org Chem</i> (2000) 65(4):1144-1157.		
	NE	WOLFE et al., "Simple, efficient catalyst system for the palladium-catalyzed amination of aryl chlorides, bromides, and triflates," <i>J Org Chem</i> (2000) 65(4):1158-1174.		
	NF	WOLTER et al., "Copper-Catalyzed Coupling of Aryl Iodides with Aliphatic Alcohols," <i>Organic Letters</i> (2002) 4(6):973-976.		
	NG	WOLTER et al., "Copper-Catalyzed Coupling of Aryl Iodides with Aliphatic Alcohols," <i>Organic Letters</i> (2002) 4(6):973-976, Supporting Information, pp. S1-S16.		

Examiner Signature	/Jeffrey Murray/	Date Considered	02/18/2009
--------------------	------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.M./

Substitute for form 1449B/PTO			<b>Complete if Known</b>		
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>			<i>Application Number</i>	10/541,657	
<i>(Use as many sheets as necessary)</i>			<i>Filing Date</i>	January 14, 2004	
Sheet	21	of	22	<i>First Named Inventor</i>	Robert M. Jones
			<i>Art Unit</i>	1624	
			<i>Examiner Name</i>	To Be Determined	
Attorney Docket Number	AREN34.US5.PCT				

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>2</sup>
	NH	WU et al., "One-Pot Two-Step Microwave-Assisted Reaction in Constructing 4,5-Disubstituted Pyrazolopyrimidines," <i>Org. Lett.</i> , (2003) 5(20):3587-3590.		
	NY	YAROVENKO et al., "New method for the preparation of 5-amino-1,2,4-oxadiazoles," <i>Bull Acad Sci, USSR Div Chem Sci</i> , (1991) 40:1924.		
	NZ	YOON et al., "Reaction of Diisobutylaluminum Hydride with Selected Organic Compounds Containing Representative Functional Groups," <i>J. Org. Chem.</i> (1985) 50:2443-2450.		
	OA	ZAMPONI et al., "Unique structure-activity relationship for 4-isoxazolyl-1,4-dihdropyridines," <i>J Med Chem</i> (2003) 46:87-96.		
	OB	ZAMPONI et al., "Unique structure-activity relationship for 4-isoxazolyl-1,4-dihdropyridines," <i>J Med Chem</i> (2003), Supporting Information., pp. 1-31.		
	OC	ZHANG, et al., "Preparation of 1-(Tri-n-Butylstannyl) Furanoid Glycals and Their Use in Palladium-Mediated Coupling Reactions," <i>Tetrahedron Letters</i> (1993) 34(10):1571-1574.		
	OD	ZHU et al., "Synthesis and mode of action of (125)I- and (3)H-labeled thieno[2,3-c]pyridine antagonists of cell adhesion molecule expression, <i>J Org Chem.</i> (2002) 67(3):943-8.		
	OE	Accession No. 2003:2415108 CHEMCATS, Interbioscreen Compound Library, Chemical Name: 1H-Pyrazolo[3,4-d]pyrimidine-4-amine, N-cyclohexyl-N-methyl-1-(3-methylphenyl)-, XP-002311326, 2003, CAS Registry No. 393844-90-1.		
	OF	Accession No. 2003:2415906 CHEMCATS, Interbioscreen Compound Library, Chemical Name: 1H-Pyrazolo[3,4-d]pyrimidine-4-amine, N-cyclohexyl-1-1-(4-methylphenyl)-, XP-002311325, 2003, CAS Registry No. 393844-89-8.		
	OG	Accession No. 2003:2416398 CHEMCATS, Interbioscreen Compound Library, Chemical Name: 1H-Pyrazolo[3,4-d]pyrimidine-4-amine, N-cyclohexyl-1-1-(2,4-dimethylphenyl)-N-methyl-, XP-002311324, 2003, CAS Registry No. 393844-91-2.		
	OH	Accession No. 2003:2417080 CHEMCATS, Interbioscreen Compound Library, Chemical Name: 1H-Pyrazolo[3,4-d]pyrimidine-4-amine, N-cyclohexyl-N-methyl-1-phenyl-, XP-002311323, 2003, CAS Registry No. 393844-87-6.		

Examiner Signature	/Jeffrey Murray/	Date Considered	02/18/2009
--------------------	------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				<i>Application Number</i>	10/541,657
(Use as many sheets as necessary)				<i>Filing Date</i>	January 14, 2004
Sheet	22	of	22	<i>First Named Inventor</i>	Robert M. Jones
				<i>Art Unit</i>	1624
				<i>Examiner Name</i>	To Be Determined
				<i>Attorney Docket Number</i>	AREN34.US5.PCT

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Description	T <sup>2</sup>
	OI	Cover Sheet and 54 Compounds - CAS Registry file (22 pp.)	
	OJ	Cover Sheet and 18 Compounds - CAS Registry file (9 pp.)	
	OK	Cover Sheet and 2534 Compounds - CAS Registry and ChemCats files (817pp.)	
	OL	Cover Sheet and 1185 Compounds - CAS Registry and ChemCats Files (391pp.)	
	OM	23 Compounds - ChemCats File (11pp.)	
	*PI	Greene et al., <i>Protective Groups in Organic Synthesis</i> , 3 <sup>rd</sup> Ed., John Wiley & Sons, New York (1999).	
	*PJ	Remington, <i>The Science and Practice of Pharmacy</i> , 20 <sup>th</sup> Ed., Lippincott Williams & Wilkins (2000).	
	*PK	Oae, <i>Organic Chemistry of Sulfur</i> , Ed., Plenum Press: New York (1977).	

Examiner Signature	/Jeffrey Murray/	Date Considered	02/18/2009
--------------------	------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option